If you are not happy with the results below please do another search
Common regulatory setting and common market for medicines have a long and difficult history. For the first time, it was mentioned in the middle of 2014, when presidents of Russian Federation, Belarus, and Kazakhstan signed a treaty on Eurasian Economic Union (EAEU). It was expected that the common market starts no later than on 01…
Roche and NICE cannot agree again, this time about the Tecentriq drug use for metastatic urothelial cancer. NICE has rejected the drug for routine use for this form of cancer in the bladder or ureter for patients who have had chemo but has invited the Swiss drugmaker to apply to the cancer drug fund (CDF),…
Thanks to the FDA’s accelerated approval Tuesday of Idhifa from partners Celgene and Axios, patients with a specific type of acute myeloid leukemia receive the first registered medication for this type of treatment. Idhifa received agency support for the treatment of patients with recurrent/refractory acute myeloid leukemia and IDH2 mutation, becoming the first drug that…
For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as other areas of business struggled. Vaccines outperformed other units at GlaxoSmithKline and Sanofi, while Merck’s immunizations posted double-digit growth. During the conference call last week, GSK executives said that vaccine production is one of three main areas…
Pfizer and its partner Astellas refused to test breast cancer drug Xtandi, that Pfizer received as one of the assets when bought Medivation for $ 14 billion last year. Xtandi has already been approved for the treatment of prostate cancer. Last year, the drug brought more than $ 2.2 billion, Astellas has also been investigating…
A specialist in rare disease drug launches, Cambridge BioMarketing has been snapped up by an Irish healthcare service provider UDG Healthcare in a $35 million deal. Buying the Massachusetts-based communications firm is part of UDG’s overseas expansion plans. While UDG is relatively unknown in the US, the Cambridge BioMarketing acquisition is the second this month…